The Journal of Korean Diabetes

Search

Page Path

HOME
Search

Focused Issues

Dipeptidyl Peptidase 4 억제제 최신지견: 이주희; J Korean Diabetes. 2021;22(2):91-96. Published online June 30, 2021; DOI: https://doi.org/10.4093/jkd.2021.22.2.91

Opinion

Dipeptidyl Peptidase-4 억제제와 Sodium Glucose Cotransporter 2 억제제의 새로운 안전성 이슈: 어떻게 해석하고 진료현장에 적용할 것인가?: Nam Hoon Kim, Sin Gon Kim; J Korean Diabetes. 2017;18(3):135-140. Published online October 12, 2017; DOI: https://doi.org/10.4093/jkd.2017.18.3.135

Original Article

시타글립틴의 혈당강하효과에 영향을 미치는 인자: Gun Woo Kim, Jae Hyun Kim, Mi Young Lee, Jang Yel Shin, Young Goo Shin, Eun Ho Ha, Choon Hee Chung; J Korean Diabetes. 2013;14(4):206-211. Published online December 24, 2013; DOI: https://doi.org/10.4093/jkd.2013.14.4.206
Cited By 1

Focused Issues

DPP-4 억제제의 췌장 외 영향 (심혈관 질환, 암, 췌장염 등): Eun Hee Cho; J Korean Diabetes. 2013;14(3):138-142. Published online September 30, 2013; DOI: https://doi.org/10.4093/jkd.2013.14.3.138

Statement

DPP-4 억제제의 비교: Nam Hoon Kim, Sin Gon Kim; J Korean Diabetes. 2013;14(3):111-119. Published online September 30, 2013; DOI: https://doi.org/10.4093/jkd.2013.14.3.111
Cited By 3

Volume 25, No. 4

The Journal of
Korean Diabetes

Print ISSN: 2233-7431
Online ISSN: 2714-0547

MOST VIEWED

3,415	Guidelines for the Use of 2023 Food Exchange Lists for Diabetes Meal Planning
5,544	Revisiting the Diabetes Crisis in Korea: Call for Urgent Action
1,808	Community-Based Intervention for Elderly Patients with Diabetes Mellitus: Assessing the Effectiveness of a YouTube Self-Education Program during the Global COVID-19 Pandemic
2,639	SGLT2 Inhibitors and Diabetes: Where Does It Come from and Where Does It Go?
964	Diabetes and Dietary Proteins-Protein Supplement Intake

Editorial Office: 101-2104, Lotte Castle President, 109 Mapo-daero, Mapo-gu, Seoul 04146, Korea
Tel: +82-2-714-9064 Fax: +82-2-714-9084 E-mail: diabetes@kams.or.kr

Copyright © 2025 by Korean Diabetes Association. All rights reserved.